Into another dimension: Assessing novel therapeutics in a more lifelike microenvironment

Our plain-English summary of Into another dimension: Assessing novel therapeutics in a more lifelike microenvironment, by M.B. Antonoff (The Journal of Thoracic and Cardiovascular Surgery, 2015).

The study

• Author: M.B. Antonoff
• Journal: The Journal of Thoracic and Cardiovascular Surgery
• Published: 2015;149(5):1426-7
• Type of article: Editorial, Comment
• Read it: PubMed · Publisher

In plain English

This article was an editorial commentary, not a research study. It discussed a separate study by Lei and colleagues, published in the same journal issue, that tested the chemotherapy drug paclitaxel carried in tiny particles called paclitaxel-loaded expansile nanoparticles against mesothelioma. The commentary reported no new data of its own and did not address asbestos exposure. As the author described it, earlier work by the same research group in 2011 had found that the nanoparticles worked better than conventional delivery of the drug in mice, a result that single-layer (monolayer) cell cultures had not predicted. According to the commentary, Lei and colleagues found that three-dimensional clusters of cells, called spheroids, more closely matched the mouse results. They also identified macropinocytosis, a way cells take in material, as the main route by which the nanoparticles entered cells. In the author's view, the study's main contribution was its use of the spheroid model. The author noted limitations that Lei and colleagues had identified: spheroids may lack the multiple cell types seen in real tumors, and measuring results in this model may be difficult.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Editorial commentary on another study; no original data
• Who was studied: No population was studied. The commentary discussed a laboratory study by Lei and colleagues in the same journal issue, which used mesothelioma cells grown as three-dimensional spheroids, and earlier mouse experiments by the same group.
• Exposure: Not an asbestos exposure study. The treatment discussed was paclitaxel delivered in expansile nanoparticles (Pax-eNPs), compared with conventional paclitaxel delivery.
• Main results:
  • As described by the commentary, the 2011 work by Colson and colleagues found that delivery by Pax-eNP was superior to conventional drug delivery in mice (in vivo). Monolayer cell culture experiments had not predicted this.
  • As described by the commentary, Lei and colleagues found that a three-dimensional spheroid model more closely replicated the mouse xenograft environment, and that Pax-eNPs were similarly superior in it.
  • As described by the commentary, Lei and colleagues identified macropinocytosis as the dominant pathway by which cells took up the expansile nanoparticles.
• The authors' conclusion: The author argued that the main impact of the Lei study may lie in its successful use of an unconventional (spheroid) tumor model, more than in its findings about mesothelioma treatment.
• Limitations the authors state:
  • The author noted, as identified by Lei and colleagues, that the spheroid model may lack the multiple cell types found in actual tumors.
  • The author noted, as identified by Lei and colleagues, that quantitative assessment may be difficult in the spheroid model.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Related studies

• Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids — H. Lei, S.C. Hofferberth, et al. (2015)
• Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma — R. Liu, A.H. Colby, et al. (2016)
• Paclitaxel-loaded expansile nanoparticles in a multimodal treatment model of malignant mesothelioma — M.D. Schulz, K.A. Zubris, et al. (2011)
• Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group — J. van Meerbeeck, C. Debruyne, et al. (1996)
• Malignant pleural mesothelioma: a phase II trial with docetaxel — D.A. Vorobiof, B.L. Rapoport, et al. (2002)
• Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series — P.H. Sugarbaker, O.A. Stuart (2020)

Browse more research in The Journal of Thoracic and Cardiovascular Surgery, or return to medical research.